Transaction · 0001636282-26-000107

Turtle Cameron

Turtle Cameron, CEO, reported an open-market or private sale at Spyre Therapeutics, Inc. involving 3700.000000 shares for an estimated $325822.00. Reported holdings after the transaction were 552940.000000 shares. The stored filing text includes a detected 10b5-1 reference.

Open-market sellSEC transaction code SCEO
SYRESpyre Therapeutics, Inc.
Filing timeSep 04
Trade dateSep 01, 2026
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
$87.25
Pre-filing
1mo ago +12.7%1w ago +24.7%1d ago +2.4%
Returns since
7d +0.0%30d +0.0%90d +0.0%180d +0.0%1y +0.0%

SYRE price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
SYRE since 2026-09-04Filed today · pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001636282-26-000107
Common Stock
Transaction date
Sep 01, 2026
Filed Sep 04, 2026, 01:33 AM · 3d delay
Shares
3.70k sh
$8.80k per share
Estimated value
-$32.5M
Computed from shares × price
Holdings after
552k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Direct Ownership Repeat Seller 10b5-1 Detected
-4score
Filing-only score

-4

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief Executive Officer

Officer YesDirector Yes10% NoOther No
Footnotes & amended
  1. F1

    This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.

  2. F2

    The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $85.67 to $86.66, inclusive. The Reporting Person undertakes to provide to

  3. the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate p…

  4. within the range.

  5. F3

    Includes 43,593 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date.

  6. F4

    The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $86.67 to $87.65, inclusive. The Reporting Person undertakes to provide to

  7. (3 footnotes)

    the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

  8. F5

    The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $87.68 to $88.67, inclusive. The Reporting Person undertakes to provide to

  9. F6

    The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.69 to $89.38, inclusive. The Reporting Person undertakes to provide to

Original filing · 0001636282-26-000107
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

SYRE